VRTX - VERTEX PHARMACEUTICALS INC / MA
IEX Last Trade
407.73
-2.320 -0.569%
Share volume: 20,319
Last Updated: Fri 03 Jan 2025 08:30:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.16%
PREVIOUS CLOSE
CHG
CHG%
$410.05
-2.32
-0.57%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2023-05-02 | 2023-08-02 | 2023-11-07 | 2024-02-15 | 2024-05-07 | 2024-08-02 | |
| Assets | |||||||
| Total Assets | 18.974 B | 20.349 B | 21.726 B | 22.730 B | 23.917 B | 20.132 B | |
| Current Assets | 12.966 B | 13.873 B | 14.696 B | 14.144 B | 13.289 B | 8.942 B | |
| Inventories | 535.100 M | 603.500 M | 688.700 M | 738.800 M | 813.100 M | 914.600 M | |
| Other Current Assets | 468.700 M | 476.900 M | 540.200 M | 623.700 M | 511.100 M | 575.400 M | |
| Short Term Investments | 468.700 M | 476.900 M | 540.200 M | 623.700 M | 511.100 M | 575.400 M | |
| Total Receivables | 1.548 B | 1.556 B | 1.539 B | 1.563 B | 1.793 B | 1.656 B | |
| Current Cash | 10.414 B | 11.236 B | 11.928 B | 11.218 B | 10.171 B | 5.796 B | |
| Total Non-current Assets | 6.009 B | 6.476 B | 7.030 B | 8.586 B | 10.629 B | 11.191 B | |
| Property Plant Equipment | 1.112 B | 1.122 B | 1.124 B | 1.159 B | 1.173 B | 1.201 B | |
| Other Assets | 328.900 M | 344.100 M | 376.600 M | 796.700 M | 801.400 M | 915.600 M | |
| Intangible Assets | 603.600 M | 603.600 M | 603.600 M | 839.900 M | 834.900 M | 837.500 M | |
| Goodwill | 1.088 B | 1.088 B | 1.088 B | 1.088 B | 1.088 B | 1.088 B | |
| Liabilities and shareholders’ equity | |||||||
| Total Liabilities and shareholders’ equity | 18.974 B | 20.349 B | 21.726 B | 22.730 B | 23.917 B | 20.132 B | |
| Total liabilities | 4.542 B | 4.879 B | 5.213 B | 5.150 B | 5.371 B | 5.357 B | |
| Total current liabilities | 3.026 B | 3.352 B | 3.599 B | 3.547 B | 3.796 B | 3.547 B | |
| Accounts Payable | 323.200 M | 363.000 M | 375.900 M | 364.900 M | 351.400 M | 327.900 M | |
| Other liabilities | 726.500 M | 759.300 M | 869.300 M | 877.700 M | 853.600 M | 876.800 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 50.600 M | 0.000 | 0.000 | |
| Long term debt | 417.600 M | 404.100 M | 390.300 M | 376.100 M | 361.500 M | 346.600 M | |
| Other liabilities | 726.500 M | 759.300 M | 869.300 M | 877.700 M | 853.600 M | 876.800 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 14.432 B | 15.470 B | 16.513 B | 17.580 B | 18.547 B | 14.775 B | |
| Common stock | 257.400 M | 257.700 M | 258.000 M | 257.700 M | 258.200 M | 258.100 M | |
| Retained earnings | 7.223 B | 8.138 B | 9.174 B | 10.142 B | 11.242 B | 7.648 B |